Halozyme CEO Helen Torley sells 60,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Halozyme Therapeutics president and CEO Helen Torley exercised stock options covering 60,000 shares and sold 60,000 common shares across November 12, November 13, and November 16, 2026. The options had exercise prices of $16.65 and $18.41 per share. The exercises and sales were made under a written Rule 10b5-1 trading plan adopted December 3, 2025.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock F1, F12 | 20,000 | $16.65 | $333K |
| Exercise | Common Stock F1 | 20,000 | $16.65 | $333K |
| Sale | Common Stock F1, F6 | 7,283 | $96.848 | $705K |
| Sale | Common Stock F1, F7 | 4,802 | $97.955 | $470K |
| Sale | Common Stock F1, F8 | 1,586 | $98.891 | $157K |
| Sale | Common Stock F1, F9 | 4,897 | $100.096 | $490K |
| Sale | Common Stock F1, F10 | 1,244 | $101.059 | $126K |
| Sale | Common Stock F1 | 188 | $101.72 | $19K |
| Exercise | Option to Purchase Common Stock F1, F11 | 1,552 | $18.41 | $29K |
| Exercise | Option to Purchase Common Stock F1, F12 | 18,448 | $16.65 | $307K |
| Exercise | Common Stock F1 | 1,552 | $18.41 | $29K |
| Exercise | Common Stock F1 | 18,448 | $16.65 | $307K |
| Sale | Common Stock F1, F4 | 7,992 | $100.019 | $799K |
| Sale | Common Stock F1, F5 | 12,008 | $100.614 | $1.21M |
| Exercise | Option to Purchase Common Stock F1, F11 | 20,000 | $18.41 | $368K |
| Exercise | Common Stock F1 | 20,000 | $18.41 | $368K |
| Sale | Common Stock F1, F2 | 10,711 | $101.093 | $1.08M |
| Sale | Common Stock F1, F3 | 9,289 | $101.494 | $943K |
Footnotes (12)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year terms expiring in February 2028 and February 2029.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.340 to $101.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.340 to $101.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.337 to $100.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.360 to $101.066. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $96.440 to $97.420. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $97.490 to $98.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.520 to $99.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.703 to $100.650. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $100.710 to $101.643. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F11. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
- F12. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 12, 2019.
Key Figures
Key Terms
Rule 10b5-1 regulatory
weighted average sales price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.